Aardvark Therapeutics is a San Diego biopharmaceutical company developing oral medicines that aim to reduce hunger in metabolic conditions. AARD reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 27 | Jones Trading | Maintained | Buy | |
| Oct 26 | HC Wainwright & Co. | Target lowered | Hold | |
| Oct 19 | HC Wainwright & Co. | Target lowered | Hold | |
| Jul 20 | HC Wainwright & Co. | Reiterated | Hold | |
| May 15 | Morgan Stanley | Downgrade | Sell |
Whale Options Flow
90DNo whale options trades in AARD in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AARD is in one of them and how their past AARD trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AARD in an article yet. Here's the latest on the wider market.
About Aardvark Therapeutics
Aardvark Therapeutics is a biopharmaceutical company based in San Diego, California, that develops small molecule medicines aimed at reducing hunger. Its work centers on compounds that act on bitter taste receptors in the gut, which are designed to prompt the body to release its own appetite-related hormones. Its lead candidate, ARD-101, is an oral drug being studied for hyperphagia, an extreme hunger condition associated with Prader-Willi syndrome. The company has no approved products yet and aims to serve patients with metabolic conditions and the clinicians who treat them.
- Headquarters
- San Diego, CA